Navigation Links
Expanding drug development horizons: Receptor behaviors observed in living cell membranes
Date:2/7/2011

Kyoto, Japan -- Unprecedented single molecule imaging movies of living cell membranes, taken by a research team based at Kyoto University and the University of New Mexico, have clarified a decades-old enigma surrounding receptor molecule behaviors. The results, appearing in the latest issue of the Journal of Cell Biology, promise to open the door to new possibilities for drug development.

The work focuses on G protein-coupled receptors (GPCRs), a class of molecules in cell membranes that comprise the largest superfamily in the human genome. In spite of being the focus of roughly half of modern drug development due to their key role in signaling across the membrane, until now it has not been well understood how GPCRs relay signals from the outside world into cells' interiors.

For over 15 years, debate regarding GPCRs' signaling mechanisms has centered on whether these molecules work alone (as monomers) or in pairs (dimers). Using formyl-peptide receptors (FPRs) as a model GPCR, the research team found that the two views are both partially correct.

"By developing a super-quantitation single-molecule imaging method, in which GPCR molecules are inspected one by one in living cell membranes," explained Rinshi Kasai of Kyoto University's Institute for Integrated Cell-Material Sciences (iCeMS) and lead author of the paper, "we are now able to actually 'see' that each individual FPR molecule moves around in the cell membrane, endlessly interconverting between monomers and dimers with different partners, completing each cycle within a quarter of a second."

According to iCeMS Professor Akihiro Kusumi, "We obtained a parameter called the dissociation constant, which will allow us to predict numbers of monomers and dimers if the total number of GPCRs in a cell is known. The ability of scientists to obtain such key numbers will be essential for understanding GPCR signaling, as well as defects leading to diseases from the neuronal to the immune systems. The implications for drug design, blocking signal amplification by monomer-dimer interconversion, are profoundly important."

The research team, funded in part by the Japan Science and Technology Agency (JST) and the Japanese education ministry MEXT, anticipates that their findings will have a broad impact on the further study of signal transduction in the cell membrane and conceptual and methodological development for drug discovery.


'/>"/>

Contact: Yutaka Iijima
yutaka-iijima@icems.kyoto-u.ac.jp
Institute for Integrated Cell-Material Sciences, Kyoto University
Source:Eurekalert

Related biology technology :

1. Safe and Secure TV Channel Expanding Programming and Revenue Agreements for 2011 with Pentagons Military News Channel and other Security Industry Leaders
2. Oridion Signs New Distributor Agreement With IMI Expanding its Presence in the Japanese Market
3. San Diego Region Awarded $4 Million Workforce Development Grant to Support Expanding Biofuels Industry
4. No Economic Slowdown for Expanding U.S. Medical Manufacturer
5. SynCo Bio Partners Increases its Capacities by Expanding its Quality Team
6. Expanding Indianas Breakthroughs in Health Information Technology (Exibhit Indiana): Initiative to Advance the States Health IT National Leadership and Assets Launched to Bring More Awareness to Sector
7. Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore
8. Robust Annual Growth Through 2012 in the Age-Related Macular Degeneration Market Will Be Driven by Expanding Use of Lucentis in Europe
9. Rapidly Expanding Ohio Bioscience Industry Drives New Workforce Training Program
10. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
11. ALS Therapy Development Institute Appoints Anil Godhwani to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... integration, today announced that it has become a Wonderware Certified System Integrator Partner. ... Integrator Partner by Schneider Electric Software. , “The System Integrator Partner certification gives ...
(Date:12/7/2016)... 2016 /PRNewswire/ - OncoQuest Inc. ("OncoQuest"), a biopharmaceutical ... immunotherapeutic products for the treatment of cancer, today ... Manufacturing Development Program with Cytovance Biologics ( ... oregovomab antibody product. Supported by recent positive interim ... in ovarian cancer patients, OncoQuest has engaged Cytovance ...
(Date:12/7/2016)... 7, 2016  Nordion, a standalone business of ... welcome today,s award by the United States Department ... of the Phase II cooperative agreement funding to ... the University of Missouri Research Reactor Center (MURR ... the establishment of a new, reliable supply of ...
Breaking Biology Technology:
(Date:11/21/2016)... VILNIUS, Lithuania , Nov. 21, 2016 /PRNewswire/ ... identification and object recognition technologies, today announced that ... for smart cards was submitted for the ... and successfully passed all the mandatory steps of ... III evaluation is a continuing test of fingerprint ...
(Date:11/16/2016)... Nov. 16, 2016 Sensory Inc ., ... security for consumer electronics, and VeriTran , ... retail industry, today announced a global partnership that ... to authenticate users of mobile banking and mobile ... software which requires no specialized biometric scanners, ...
(Date:11/14/2016)... 14, 2016  Based on its recent ... & Sullivan recognizes FST Biometrics with the ... Visionary Innovation Leadership. FST Biometrics emerged as ... market by pioneering In Motion Identification (IMID) ... seamless, and non-invasive verification. This patented solution ...
Breaking Biology News(10 mins):